Moffitt signs deal with Swiss firm Debiopharm - Tampa Bay Business Journal:

ignatiywulyxura.blogspot.com
Under terms of the agreement, Debiopharm will pay Moffittt anupfront fee, as well as predefined advancedx milestone payments during the development of the a release said. The payment terms were not The agreementgives Debiopharm, a global biopharmaceutical groupo of companies based in an exclusive license to develop and commercialize Debio a small molecule in early preclinical development. The molecul prevents an interaction that of two creating a new strategy in the fightagainst cancer, the release said. The discover y was the result of collaborationjbetween Drs. Srikumar Chellappan, Said Sebtiu and Nicholas Lawrenceat Moffitt.
Debik 0928 is a therapeuticv strategy with the potential for targeting a wide range ofhuman cancers, Sebti, chaifr of the department of drug discoveryt at Moffitt, said in the release. The in Tampa is the only Florida-based cancer center designated as a Comprehensivde Cancer Center bythe .